ZD6474(Vandetanib) + Alimta Combo Study

NCT00506051 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma
Non-Small Cell Lung
Lung Cancer

Interventions

DRUG: ZD6474 (vandetanib) 100mg
DRUG: pemetrexed
DRUG: ZD6474 (vandetanib) 300mg

Sponsor

Genzyme, a Sanofi Company